Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
Status:
COMPLETED
Trial end date:
2025-04-29
Target enrollment:
Participant gender:
Summary
The goal of this project is to collect data regarding the concentrations of doxycycline in mucosal tissues after daily dosing for 7 days in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB) to inform future studies of doxycycline to protect against bacterial sexually transmitted infections (STIs).